Herpes simplex virus replication machinery

The Herpes simplex virus (HSV) replication machinery is a coordinated multi-protein system essential for the synthesis and amplification of the viral double-stranded DNA genome during the lytic phase of infection (Source: NIH [1.2.1, 1.4.1]). It comprises seven core viral proteins: the UL30 DNA polymerase, the UL42 processivity factor, the UL5/UL8/UL52 helicase-primase complex, the UL29 (ICP8) single-stranded DNA-binding protein, and the UL9 origin-binding protein (Source: NIH [1.2.2, 1.4.2]). These proteins assemble at specific viral origins (oriS and oriL) to initiate DNA synthesis, transitioning from theta-type replication to rolling-circle replication to produce the long concatemers required for virion assembly (Source: NIH [1.4.1, 1.4.4]). This machinery serves as the primary target for anti-herpetic drugs due to its high selectivity over host cell replication factors (Source: NIH [1.2.1, 1.3.2]). Traditional nucleoside analogs like acyclovir and penciclovir target the UL30 DNA polymerase, acting as chain terminators after being selectively phosphorylated by viral thymidine kinase (Source: Medscape [1.3.4, 1.5.2]). Newer therapeutic classes, such as helicase-primase inhibitors (e.g., pritelivir and amenamevir), directly block the unwinding of viral DNA, offering efficacy against strains resistant to polymerase inhibitors (Source: NIH, PatSnap [1.3.1, 1.3.5]). Despite their clinical success in reducing symptoms and transmission, these agents cannot eliminate the latent viral reservoir in the host's nervous system, and the development of resistance in immunocompromised populations remains a significant concern (Source: NIH [1.3.2, 1.5.2]).

Other names

HSV replication complexHSV replisomeHSV DNA replication machineryHSV replication proteins

Inhibition of viral DNA polymerase through competitive substrate binding and DNA chain termination; inhibition of the helicase-primase complex to prevent DNA unwinding and RNA primer synthesis.